biorelate limited
biorelate limited Company Information
Company Number
09087514
Next Accounts
Dec 2025
Shareholders
daniel jamieson
npif nw equity lp (acting by its general partner npif nw equity (gp) ltd)
View AllGroup Structure
View All
Industry
Research and experimental development on biotechnology
Registered Address
unit 9 williams house, lloyd street north, manchester, M15 6SE
Website
www.biorelate.combiorelate limited Estimated Valuation
Pomanda estimates the enterprise value of BIORELATE LIMITED at £5m based on a Turnover of £3.5m and 1.42x industry multiple (adjusted for size and gross margin).
biorelate limited Estimated Valuation
Pomanda estimates the enterprise value of BIORELATE LIMITED at £0 based on an EBITDA of £-3m and a 5.61x industry multiple (adjusted for size and gross margin).
biorelate limited Estimated Valuation
Pomanda estimates the enterprise value of BIORELATE LIMITED at £3.7m based on Net Assets of £2.1m and 1.79x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Biorelate Limited Overview
Biorelate Limited is a live company located in manchester, M15 6SE with a Companies House number of 09087514. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in June 2014, it's largest shareholder is daniel jamieson with a 21.4% stake. Biorelate Limited is a established, small sized company, Pomanda has estimated its turnover at £3.5m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Biorelate Limited Health Check
Pomanda's financial health check has awarded Biorelate Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 4 areas for improvement. Company Health Check FAQs
2 Strong
5 Regular
4 Weak
Size
annual sales of £3.5m, make it in line with the average company (£3.6m)
- Biorelate Limited
£3.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 30%, show it is growing at a faster rate (12.7%)
- Biorelate Limited
12.7% - Industry AVG
Production
with a gross margin of 54.4%, this company has a comparable cost of product (54.4%)
- Biorelate Limited
54.4% - Industry AVG
Profitability
an operating margin of -86.8% make it less profitable than the average company (-7.5%)
- Biorelate Limited
-7.5% - Industry AVG
Employees
with 33 employees, this is below the industry average (46)
33 - Biorelate Limited
46 - Industry AVG
Pay Structure
on an average salary of £79.3k, the company has an equivalent pay structure (£79.3k)
- Biorelate Limited
£79.3k - Industry AVG
Efficiency
resulting in sales per employee of £106.5k, this is equally as efficient (£123.6k)
- Biorelate Limited
£123.6k - Industry AVG
Debtor Days
it gets paid by customers after 69 days, this is later than average (53 days)
- Biorelate Limited
53 days - Industry AVG
Creditor Days
its suppliers are paid after 28 days, this is quicker than average (53 days)
- Biorelate Limited
53 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Biorelate Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 69 weeks, this is more cash available to meet short term requirements (33 weeks)
69 weeks - Biorelate Limited
33 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 46.9%, this is a similar level of debt than the average (51.3%)
46.9% - Biorelate Limited
51.3% - Industry AVG
BIORELATE LIMITED financials
Biorelate Limited's latest turnover from March 2024 is estimated at £3.5 million and the company has net assets of £2.1 million. According to their latest financial statements, Biorelate Limited has 33 employees and maintains cash reserves of £2.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||||
| Other Income Or Grants | ||||||||||
| Cost Of Sales | ||||||||||
| Gross Profit | ||||||||||
| Admin Expenses | ||||||||||
| Operating Profit | ||||||||||
| Interest Payable | ||||||||||
| Interest Receivable | ||||||||||
| Pre-Tax Profit | ||||||||||
| Tax | ||||||||||
| Profit After Tax | ||||||||||
| Dividends Paid | ||||||||||
| Retained Profit | ||||||||||
| Employee Costs | ||||||||||
| Number Of Employees | 33 | 24 | 23 | 28 | 21 | 12 | 5 | 4 | 2 | |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 38,049 | 24,474 | 14,062 | 10,846 | 12,674 | 13,904 | 3,937 | 5,705 | 1,752 | |
| Intangible Assets | ||||||||||
| Investments & Other | ||||||||||
| Debtors (Due After 1 year) | ||||||||||
| Total Fixed Assets | 38,049 | 24,474 | 14,062 | 10,846 | 12,674 | 13,904 | 3,937 | 5,705 | 1,752 | |
| Stock & work in progress | ||||||||||
| Trade Debtors | 668,994 | 817,396 | 210,135 | 84,000 | 30,598 | 62,999 | 23,780 | |||
| Group Debtors | ||||||||||
| Misc Debtors | 812,680 | 466,176 | 273,468 | 183,352 | 158,911 | 50,238 | 29,858 | 12,367 | ||
| Cash | 2,408,476 | 5,137,938 | 749,292 | 1,278,458 | 687,218 | 348,474 | 10,297 | 28,499 | ||
| misc current assets | 480 | |||||||||
| total current assets | 3,890,150 | 6,421,510 | 1,232,895 | 1,545,810 | 876,727 | 461,711 | 24,260 | 40,155 | 40,866 | |
| total assets | 3,928,199 | 6,445,984 | 1,246,957 | 1,556,656 | 889,401 | 475,615 | 28,197 | 45,860 | 42,618 | |
| Bank overdraft | 5,369 | 7,987 | 8,656 | 8,392 | 473 | 6,153 | ||||
| Bank loan | ||||||||||
| Trade Creditors | 123,307 | 114,100 | 26,851 | 21,368 | 39,011 | 14,820 | 16,671 | |||
| Group/Directors Accounts | ||||||||||
| other short term finances | ||||||||||
| hp & lease commitments | 252 | |||||||||
| other current liabilities | 1,681,385 | 1,355,431 | 710,939 | 159,565 | 165,522 | 35,818 | 25,102 | 31,189 | ||
| total current liabilities | 1,810,061 | 1,477,518 | 746,446 | 189,325 | 204,533 | 50,638 | 16,671 | 25,827 | 37,342 | |
| loans | 30,985 | 33,604 | 726,232 | 729,535 | 50,000 | |||||
| hp & lease commitments | 3,028 | |||||||||
| Accruals and Deferred Income | 21,586 | |||||||||
| other liabilities | 91,600 | 51,767 | ||||||||
| provisions | ||||||||||
| total long term liabilities | 30,985 | 33,604 | 817,832 | 729,535 | 73,353 | 53,028 | ||||
| total liabilities | 1,841,046 | 1,511,122 | 1,564,278 | 918,860 | 204,533 | 50,638 | 90,024 | 78,855 | 37,342 | |
| net assets | 2,087,153 | 4,934,862 | -317,321 | 637,796 | 684,868 | 424,977 | -61,827 | -32,995 | 5,276 | |
| total shareholders funds | 2,087,153 | 4,934,862 | -317,321 | 637,796 | 684,868 | 424,977 | -61,827 | -32,995 | 5,276 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||
| Operating Profit | ||||||||||
| Depreciation | 13,006 | 5,961 | 5,917 | 3,598 | 4,772 | 2,359 | 788 | 583 | ||
| Amortisation | ||||||||||
| Tax | ||||||||||
| Stock | ||||||||||
| Debtors | 198,102 | 799,969 | 216,251 | 77,843 | 76,272 | 89,457 | -6,078 | 17,491 | 12,367 | |
| Creditors | 9,207 | 87,249 | 5,483 | -17,643 | 24,191 | -1,851 | 16,671 | |||
| Accruals and Deferred Income | 325,954 | 644,492 | 551,374 | -5,957 | 129,704 | 14,232 | -3,516 | -6,087 | 31,189 | |
| Deferred Taxes & Provisions | ||||||||||
| Cash flow from operations | ||||||||||
| Investing Activities | ||||||||||
| capital expenditure | ||||||||||
| Change in Investments | ||||||||||
| cash flow from investments | ||||||||||
| Financing Activities | ||||||||||
| Bank loans | ||||||||||
| Group/Directors Accounts | ||||||||||
| Other Short Term Loans | ||||||||||
| Long term loans | -2,619 | -692,628 | -3,303 | 729,535 | -50,000 | 50,000 | ||||
| Hire Purchase and Lease Commitments | -3,280 | 3,280 | ||||||||
| other long term liabilities | -91,600 | 91,600 | -51,767 | 51,767 | ||||||
| share issue | ||||||||||
| interest | ||||||||||
| cash flow from financing | ||||||||||
| cash and cash equivalents | ||||||||||
| cash | -2,729,462 | 4,388,646 | -529,166 | 591,240 | 338,744 | 348,474 | -10,297 | -18,202 | 28,499 | |
| overdraft | -2,618 | -669 | 264 | 8,392 | -473 | -5,680 | 6,153 | |||
| change in cash | -2,726,844 | 4,389,315 | -529,430 | 582,848 | 338,744 | 348,474 | -9,824 | -12,522 | 22,346 |
biorelate limited Credit Report and Business Information
Biorelate Limited Competitor Analysis
Perform a competitor analysis for biorelate limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in M15 area or any other competitors across 12 key performance metrics.
biorelate limited Ownership
BIORELATE LIMITED group structure
Biorelate Limited has no subsidiary companies.
Ultimate parent company
BIORELATE LIMITED
09087514
biorelate limited directors
Biorelate Limited currently has 3 directors. The longest serving directors include Mr Daniel Jamieson (Jun 2014) and Mr Gavin Bell (Nov 2022).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Daniel Jamieson | England | 37 years | Jun 2014 | - | Director |
| Mr Gavin Bell | Scotland | 48 years | Nov 2022 | - | Director |
| Mrs Deborah Kobewka | United Kingdom | 63 years | Mar 2023 | - | Director |
P&L
March 2024turnover
3.5m
0%
operating profit
-3.1m
0%
gross margin
54.4%
+1.01%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
2.1m
-0.58%
total assets
3.9m
-0.39%
cash
2.4m
-0.53%
net assets
Total assets minus all liabilities
biorelate limited company details
company number
09087514
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
June 2014
age
11
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
March 2024
previous names
N/A
accountant
AFFORD BOND HOLDINGS LIMITED
auditor
-
address
unit 9 williams house, lloyd street north, manchester, M15 6SE
Bank
-
Legal Advisor
-
biorelate limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 1 charges/mortgages relating to biorelate limited. Currently there are 0 open charges and 1 have been satisfied in the past.
biorelate limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BIORELATE LIMITED. This can take several minutes, an email will notify you when this has completed.
biorelate limited Companies House Filings - See Documents
| date | description | view/download |
|---|
